American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

Abstract

ASCO's update to its Clinical Practice Guideline on the use of pharmacologic interventions to reduce the risk of breast cancer addresses the roles of tamoxifen, raloxifene, aromatase inhibitors, and fenretinide in reducing risk for the disease.